Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1993 2
1994 1
1998 2
2003 5
2004 7
2005 11
2006 5
2007 6
2008 7
2009 4
2010 11
2011 7
2012 15
2013 18
2014 15
2015 9
2016 11
2017 8
2018 16
2019 8
2020 5
2021 11
2022 9
2023 10
2024 11
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Zhu HD, et al. Among authors: lu lg. Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0. Signal Transduct Target Ther. 2023. PMID: 36750721 Free PMC article.
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.
Antihepatic Fibrosis Drugs in Clinical Trials.
Guo YC, Lu LG. Guo YC, et al. Among authors: lu lg. J Clin Transl Hepatol. 2020 Sep 28;8(3):304-312. doi: 10.14218/JCTH.2020.00023. Epub 2020 Aug 24. J Clin Transl Hepatol. 2020. PMID: 33083254 Free PMC article. Review.
Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial.
Lu J, Guo JH, Ji JS, Li YL, Lv WF, Zhu HD, Sun JH, Ren WX, Zhang FJ, Wang WD, Shao HB, Cao GS, Li HL, Gao K, Yang P, Yin GW, Zhu GY, Wu FZ, Wang WJ, Lu D, Chen SQ, Min J, Zhao Y, Li R, Lu LG, Lau WY, Teng GJ. Lu J, et al. Among authors: lu lg. Int J Surg. 2023 May 1;109(5):1188-1198. doi: 10.1097/JS9.0000000000000295. Int J Surg. 2023. PMID: 37038986 Free PMC article. Clinical Trial.
[Cholesterol metabolism and non-alcoholic steatohepatitis].
Ma ZZ, Lu LG. Ma ZZ, et al. Among authors: lu lg. Zhonghua Gan Zang Bing Za Zhi. 2016 Aug 20;24(8):623-627. doi: 10.3760/cma.j.issn.1007-3418.2016.08.014. Zhonghua Gan Zang Bing Za Zhi. 2016. PMID: 27788713 Review. Chinese.
Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024).
Mao YM, Tang JT, Lu ZH, Shao M, Zhao WF, Zhan J, Huang ZX, Niu QH, Chen L, Chen ZF, Guo CH, Jia ZH, Li H, Liu B, Miao J, Peng ZT, Pu YL, Qu LH, Shen XM, Sun W, Wang HW, Lu XL, Xue JJ, Yang YY, Yang Z, Yang ZH, Zhang QG, Niu T, Zhu WD, Liu XL, Zhong W, Dong YN, Zhi Y, Li XY; Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Committee on Drug Liver Safety, China Primary Health Care Foundation; Study Group on Drug Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Mao YM, et al. J Dig Dis. 2025 Jan-Feb;26(1-2):2-21. doi: 10.1111/1751-2980.13337. Epub 2025 Apr 8. J Dig Dis. 2025. PMID: 40198161
CSH guidelines for the diagnosis and treatment of drug-induced liver injury.
Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, Hu P, Hu XQ, Jia JD, Lai RT, Li DL, Liu YX, Lu LG, Ma SW, Ma X, Nan YM, Ren H, Shen T, Wang H, Wang JY, Wang TL, Wang XJ, Wei L, Xie Q, Xie W, Yang CQ, Yang DL, Yu YY, Zeng MD, Zhang L, Zhao XY, Zhuang H; Drug-induced Liver Injury (DILI) Study Group; Chinese Society of Hepatology (CSH); Chinese Medical Association (CMA). Yu YC, et al. Among authors: lu lg. Hepatol Int. 2017 May;11(3):221-241. doi: 10.1007/s12072-017-9793-2. Epub 2017 Apr 12. Hepatol Int. 2017. PMID: 28405790 Free PMC article.
211 results